Amylin to present diabetes drug data at ADA scientific meeting

SAN DIEGO Amylin Pharmaceuticals plans to present data on two of its diabetes drugs and an investigational diabetes drug at the annual scientific meeting of the American Diabetes Association in New Orleans next month, the drug maker announced Friday.

The company will present data on the injected drugs Byetta (exenatide) and Symlin (pramlintide acetate), as well as a once-weekly formulation of exenatide. All the drugs are designed to treat Type 2 diabetes, though Symlin also treats Type 1 diabetes. Amylin markets Byetta with Indianapolis-based Eli Lilly & Co.

The company said its presentation, which will include five oral presentations and 16 posters, would demonstrate “significant progress” in key research and clinical programs for the three drugs.